Hesperidin Plays Neuroprotective Effects Against Quinolinic Acid in Human SH-SY5Y Cells: Focusing on ROS Levels and Cell Cycle Arrest

Background and objectives: In some neurodegenerative diseases, an aberrant accumulation of quinolinic acid is frequently associated with the loss of nerve cells and a condition known as neuritis. This is typically caused by an excessive production of free radicals. Studies have shown that hesperidin has potent antioxidant effects, but nothing is known about how it protects against the neurotoxicity induced by quinolinic acid. This study aimed to evaluate the protective effect of hesperidin against quinolinic acid-induced neurotoxicity in the SH-SY5Y neuroblastoma cell line. Methods: The MTT test was used to determine cell viability and protective dosage of hesperidin. Flow cytometry using propidium iodide (PI) staining was used to determine the cell cycle of SH-SY5Y cells after exposure to quinolinic acid in combination with hesperidin. Reactive oxygen species (ROS) levels within cells were also measured using 2', 7'-dichlorodihydrofluorescein diacetate (H2DCFDA) in the mentioned groups. Results: Our results demonstrated that hesperidin had a protective effect against quinolinic acid-induced toxicity at nontoxic concentrations (p<0.001). Moreover, the percentage of apoptotic cells in the sub-G1 phase increased significantly (p<0.001). Hesperidin pretreatment significantly decreased sub-G1 arrest that was induced by quinolinic acid (p<0.001). Hesperidin significantly decreased ROS levels generated by quinolinic acid (p<0.001). Conclusion: The current study showed that hesperidin exerts its effect through antioxidant activity and can be considered a promising neuroprotectant agent against quinolinic acid-induced neurotoxicity in neurodegenerative disorders; however, more research is necessary in this area for the treatment

The 10th International Conference on Ambient Systems, Networks and Technologies (ANT 2019) / The 2nd International Conference on Emerging Data and Industry 4.0 (EDI40 2019) / Affiliated Workshops

Photoplethysmography (PPG) as a non-invasive and low-cost technique plays a significant role in wearable Internet-of-Things based health monitoring systems, enabling continuous health and well-being data collection. As PPG monitoring is relatively simple, non-invasive, and convenient, it is widely used in a variety of wearable devices (e.g., smart bands, smart rings, smartphones) to acquire different vital signs such as heart rate and pulse rate variability. However, the accuracy of such vital signs highly depends on the quality of the signal and the presence of artifacts generated by other resources such as motion. This unreliable performance is unacceptable in health monitoring systems. To tackle this issue, different studies have proposed motion artifacts reduction and signal quality assessment methods. However, they merely focus on improvements in the results and signal quality. Therefore, they are unable to alleviate erroneous decision making due to invalid vital signs extracted from the unreliable PPG signals. In this paper, we propose a novel PPG quality assessment approach for IoT-based health monitoring systems, by which the reliability of the vital signs extracted from PPG quality is determined. Therefore, unreliable data can be discarded to prevent inaccurate decision making and false alarms. Exploiting a Convolutional Neural Networks (CNN) approach, a hypothesis function is created by comparing heart rate in the PPG with corresponding heart rate values extracted from ECG signal. We implement a proof-of-concept IoT-based system to evaluate the accuracy of the proposed approach.</p

International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis

Abstract Importance: A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because methotrexate is affordable and globally available, a uniform dosing regimen could potentially optimize the treatment of patients with psoriasis worldwide. Objective: To reach international consensus among psoriasis experts on a uniform dosing regimen for treatment with methotrexate in adult and pediatric patients with psoriasis and identify potential future research topics. Design, setting, and participants: Between September 2020 and March 2021, a survey study with a modified eDelphi procedure that was developed and distributed by the Amsterdam University Medical Center and completed by 180 participants worldwide (55 [30.6%] resided in non-Western countries) was conducted in 3 rounds. The proposals on which no consensus was reached were discussed in a conference meeting (June 2021). Participants voted on 21 proposals with a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree) and were recruited through the Skin Inflammation and Psoriasis International Network and European Academy of Dermatology and Venereology in June 2020. Apart from being a dermatologist/dermatology resident, there were no specific criteria for participation in the survey. The participants worked mainly at a university hospital (97 [53.9%]) and were experienced in treating patients with psoriasis with methotrexate (163 [91.6%] had more than 10 years of experience). Main outcomes and measures: In a survey with eDelphi procedure, we tried to reach consensus on 21 proposals. Consensus was defined as less than 15% voting disagree (1-3). For the consensus meeting, consensus was defined as less than 30% voting disagree. Results: Of 251 participants, 180 (71.7%) completed all 3 survey rounds, and 58 participants (23.1%) joined the conference meeting. Consensus was achieved on 11 proposals in round 1, 3 proposals in round 2, and 2 proposals in round 3. In the consensus meeting, consensus was achieved on 4 proposals. More research is needed, especially for the proposals on folic acid and the dosing of methotrexate for treating subpopulations such as children and vulnerable patients. Conclusions and relevance: In this eDelphi consensus study, consensus was reached on 20 of 21 proposals involving methotrexate dosing in patients with psoriasis. This consensus may potentially be used to harmonize the treatment with methotrexate in patients with psoriasis

International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients with Psoriasis

Importance: A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because methotrexate is affordable and globally available, a uniform dosing regimen could potentially optimize the treatment of patients with psoriasis worldwide. Objective: To reach international consensus among psoriasis experts on a uniform dosing regimen for treatment with methotrexate in adult and pediatric patients with psoriasis and identify potential future research topics. Design, Setting, and Participants: Between September 2020 and March 2021, a survey study with a modified eDelphi procedure that was developed and distributed by the Amsterdam University Medical Center and completed by 180 participants worldwide (55 [30.6%] resided in non-Western countries) was conducted in 3 rounds. The proposals on which no consensus was reached were discussed in a conference meeting (June 2021). Participants voted on 21 proposals with a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree) and were recruited through the Skin Inflammation and Psoriasis International Network and European Academy of Dermatology and Venereology in June 2020. Apart from being a dermatologist/dermatology resident, there were no specific criteria for participation in the survey. The participants worked mainly at a university hospital (97 [53.9%]) and were experienced in treating patients with psoriasis with methotrexate (163 [91.6%] had more than 10 years of experience). Main Outcomes and Measures: In a survey with eDelphi procedure, we tried to reach consensus on 21 proposals. Consensus was defined as less than 15% voting disagree (1-3). For the consensus meeting, consensus was defined as less than 30% voting disagree. Results: Of 251 participants, 180 (71.7%) completed all 3 survey rounds, and 58 participants (23.1%) joined the conference meeting. Consensus was achieved on 11 proposals in round 1, 3 proposals in round 2, and 2 proposals in round 3. In the consensus meeting, consensus was achieved on 4 proposals. More research is needed, especially for the proposals on folic acid and the dosing of methotrexate for treating subpopulations such as children and vulnerable patients. Conclusions and Relevance: In this eDelphi consensus study, consensus was reached on 20 of 21 proposals involving methotrexate dosing in patients with psoriasis. This consensus may potentially be used to harmonize the treatment with methotrexate in patients with psoriasis.